Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Amgen to Acquire ChemoCentryx in $3.7bn Deal

Stock Markets Aug 04, 2022 03:07PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Amgen (AMGN) to Acquire ChemoCentryx (CCXI) in $3.7bn Deal

By Sam Boughedda

Amgen (NASDAQ:AMGN) is set to acquire ChemoCentryx (NASDAQ:CCXI) for $52 per share in cash, it was announced Thursday, representing an enterprise value of approximately $3.7 billion.

The transaction, which is subject to ChemoCentryx stockholder approval, is expected to close in the fourth quarter of 2022.

"The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with TAVNEOS, a transformative, first-in-class treatment for ANCA-associated vasculitis," said Robert Bradway, chairman and chief executive officer at Amgen.

A Mizuho analyst, who maintained a Neutral rating and $208 price target in a note following the announcement, said, "Amgen announced the acquisition of ChemoCentryx (CCXI, not covered) for ~$4Bn; <3x peak sales multiple by our math (so seems reasonable for Amgen), and also generally good for biotech tape with >100% premium paid to yesterday's close."

"Tavneos is an oral, FDA-approved add-on drug for adults with a rare form of blood vessel inflammation called severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis," added the analyst. "Consensus WW peak sales for Tavneos in ANCA-associated vasculitis is ~$1000MM, a bit below our preliminary math of ~$, <3x peak sales multiple on the deal on this asset and indication alone, seems reasonable for Amgen."

Elsewhere, a BMO Capital Markets analyst said, in a note titled "Biotech Is Back!?,the "main driver is Tavneos (avacopan)."

"1Q22 revs were $5.4M while consensus expects $66M in FY22, $200M in FY23 and upside to $1.7B by 2030 with Hidradenitis Suppurativa and C3 Glomerulopathy. Deal seems commercially driven, given limited pipeline (one Ph 2skin/GI asset, one Ph 1 oral PDL1/PD1i)," added the analyst, who has a Market Perform rating and $251 price target on Amgen.

Amgen to Acquire ChemoCentryx in $3.7bn Deal

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email